Marina Biotech this week announced that the Intellectual Property Office of New Zealand said it will grant the company a patent covering its unlocked nucleobase analog technology.
The deal with an undisclosed "major pharmaceutical company" is focused on the evaluation of Marina's proprietary amphoteric liposomal formulations for pulmonary delivery.
According to MDRNA, the application claims siRNAs and delivery systems with therapeutic potential.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.